[
  {
    "ts": "2025-12-11T08:12:39+00:00",
    "headline": "The Bull Case For Johnson & Johnson (JNJ) Could Change Following New Multiple Myeloma Breakthrough Data",
    "summary": "Johnson & Johnson recently reported Phase 3 data showing that its TECVAYLI plus DARZALEX FASPRO combination cut the risk of disease progression or death for relapsed or refractory multiple myeloma patients and secured US FDA Breakthrough Therapy Designation, while updated CARVYKTI results pointed to durable, treatment-free remissions with earlier-line use. Together, these oncology data reinforce Johnson & Johnson’s push into next-generation blood cancer therapies, potentially reshaping...",
    "url": "https://finance.yahoo.com/news/bull-case-johnson-johnson-jnj-081239380.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9497363c-f71e-38eb-b86f-b65232ed0f91",
      "content": {
        "id": "9497363c-f71e-38eb-b86f-b65232ed0f91",
        "contentType": "STORY",
        "title": "The Bull Case For Johnson & Johnson (JNJ) Could Change Following New Multiple Myeloma Breakthrough Data",
        "description": "",
        "summary": "Johnson & Johnson recently reported Phase 3 data showing that its TECVAYLI plus DARZALEX FASPRO combination cut the risk of disease progression or death for relapsed or refractory multiple myeloma patients and secured US FDA Breakthrough Therapy Designation, while updated CARVYKTI results pointed to durable, treatment-free remissions with earlier-line use. Together, these oncology data reinforce Johnson & Johnson’s push into next-generation blood cancer therapies, potentially reshaping...",
        "pubDate": "2025-12-11T08:12:39Z",
        "displayTime": "2025-12-11T08:12:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-johnson-johnson-jnj-081239380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-johnson-johnson-jnj-081239380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:50:16+00:00",
    "headline": "Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]",
    "url": "https://finance.yahoo.com/news/guggenheim-highlights-growth-potential-johnson-075016413.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "bc280d56-8f9f-309b-8cbc-acbacd0458ad",
      "content": {
        "id": "bc280d56-8f9f-309b-8cbc-acbacd0458ad",
        "contentType": "STORY",
        "title": "Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]",
        "pubDate": "2025-12-11T07:50:16Z",
        "displayTime": "2025-12-11T07:50:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-highlights-growth-potential-johnson-075016413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-highlights-growth-potential-johnson-075016413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T09:54:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries",
    "summary": "AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-broadcom-095400424.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "63363cdb-fea2-342a-b879-605c70362f6f",
      "content": {
        "id": "63363cdb-fea2-342a-b879-605c70362f6f",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries",
        "description": "",
        "summary": "AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.",
        "pubDate": "2025-12-11T09:54:00Z",
        "displayTime": "2025-12-11T09:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/220280fc7469797653572e9fff387e53",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gs5YS4e0vycKJHgAYkRU2A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/220280fc7469797653572e9fff387e53.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ltGIXX80iQOYZsofPfzVKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/220280fc7469797653572e9fff387e53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-broadcom-095400424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-broadcom-095400424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "XOM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ITIC"
            },
            {
              "symbol": "FRD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:46:55+00:00",
    "headline": "Pharma’s top deals in 2025",
    "summary": "The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.",
    "url": "https://www.pharmavoice.com/news/pharma-deal-2025-jnj-novartis-pfizer-metsera-drug/807610/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "d87f7b86-f87f-31b3-86ad-ff843304773d",
      "content": {
        "id": "d87f7b86-f87f-31b3-86ad-ff843304773d",
        "contentType": "STORY",
        "title": "Pharma’s top deals in 2025",
        "description": "",
        "summary": "The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.",
        "pubDate": "2025-12-11T07:46:55Z",
        "displayTime": "2025-12-11T07:46:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/6a30da6d35c4111d86d8ea4c5a8ebff8",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Johnson & Johnson won U.S. approval on April 30, 2025, of its new drug Imaavy for generalized myasthenia gravis.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IVP0bFSzV7dnEHje_HIN3g--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/6a30da6d35c4111d86d8ea4c5a8ebff8.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n8IuBwvDqSVTf4WkababRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/6a30da6d35c4111d86d8ea4c5a8ebff8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/pharma-deal-2025-jnj-novartis-pfizer-metsera-drug/807610/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-top-deals-2025-074655526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]